Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.

Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, Peiteado D, Arribas F, Díez J, López-Casla MT, Martín-Mola E, Balsa A.

Arthritis Res Ther. 2013 Jul 26;15(4):R79. doi: 10.1186/ar4258.

2.

Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.

Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G.

Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11.

PMID:
20223813
3.

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.

Scirè CA, Caporali R, Sarzi-Puttini P, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, Delsante G, Porru G, Salaffi F, Giuggioli D, Rossini M, Todoerti M, Bazzichi L, Govoni M, Gerli R, Raschetti R, Minisola G, Montecucco C, Todesco S; Monitornet project..

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):857-63. Epub 2013 Aug 26.

PMID:
23981363
4.

Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis.

Baser O, Ganguli A, Roy S, Xie L, Cifaldi M.

Clin Ther. 2015 Jul 1;37(7):1454-65. doi: 10.1016/j.clinthera.2015.04.012. Epub 2015 May 18.

5.

Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.

Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, Díez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A.

Ann Rheum Dis. 2012 Dec;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828. Epub 2012 May 6.

PMID:
22563028
6.

Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.

Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G.

Rheumatology (Oxford). 2014 May;53(5):875-81. doi: 10.1093/rheumatology/ket433. Epub 2014 Jan 9.

PMID:
24407233
7.

Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.

Spadaro A, Lubrano E, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Perrotta FM, Olivieri I, Punzi L, Salvarani C.

Rheumatology (Oxford). 2013 Oct;52(10):1914-9. doi: 10.1093/rheumatology/ket249. Epub 2013 Jul 22.

PMID:
23878312
8.

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.

Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.

PMID:
21068090
9.

Drug survival of anti-tumour necrosis factor α therapy in spondyloarthropathies: results from the Spanish emAR II Study.

Rosales-Alexander JL, Balsalobre Aznar J, Pérez-Vicente S, Magro-Checa C.

Rheumatology (Oxford). 2015 Aug;54(8):1459-63. doi: 10.1093/rheumatology/kev001. Epub 2015 Mar 12.

PMID:
25767155
10.

Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.

Arstikyte I, Kapleryte G, Butrimiene I, Venalis A.

Biomed Res Int. 2015;2015:604872. doi: 10.1155/2015/604872. Epub 2015 Apr 27.

11.

Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides.

Biggioggero M, Favalli EG.

Drug Dev Res. 2014 Nov;75 Suppl 1:S38-41. doi: 10.1002/ddr.21192.

PMID:
25381973
12.

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.

Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R; ARTIS group..

Ann Rheum Dis. 2015 May;74(5):890-6. doi: 10.1136/annrheumdis-2013-204714. Epub 2014 Jan 15.

PMID:
24431398
13.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

14.

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP; BSR Biologics Register..

Rheumatology (Oxford). 2008 Jul;47(7):1000-5. doi: 10.1093/rheumatology/ken127. Epub 2008 Apr 17.

15.

Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.

Ciurea A, Exer P, Weber U, Tamborrini G, Steininger B, Kissling RO, Bernhard J, Scherer A; Rheumatologists of Swiss Clinical Quality Management Program for Axial Spondyloarthritis..

Arthritis Res Ther. 2016 Mar 22;18:71. doi: 10.1186/s13075-016-0969-2.

16.

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis.

Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, Vegh E, Szabo Z, Szucs G, Szekanecz Z, Szanto S.

Eur J Health Econ. 2014 May;15 Suppl 1:S93-100. doi: 10.1007/s10198-014-0598-0. Epub 2014 May 16.

PMID:
24832840
17.

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rødevand E, Koldingsnes W, Kaufmann C, Kvien TK.

Ann Rheum Dis. 2011 Jan;70(1):157-63. doi: 10.1136/ard.2010.131797. Epub 2010 Nov 9.

PMID:
21062852
18.

Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.

DI Franco M, Paradiso M, Ceccarelli F, Scrivo R, Spinelli FR, Iannuccelli C, Valesini G.

J Rheumatol. 2012 Jan;39(1):41-5. doi: 10.3899/jrheum.110158. Epub 2011 Nov 1.

PMID:
22045840
19.

Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment.

Paramarta JE, De Rycke L, Ambarus CA, Tak PP, Baeten D.

Rheumatology (Oxford). 2013 Oct;52(10):1873-8. doi: 10.1093/rheumatology/ket239. Epub 2013 Jul 16.

PMID:
23861532
20.

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.

van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, Rudwaleit M, Braun J; Assessment of SpondyloArthritis international Society..

Ann Rheum Dis. 2011 Jun;70(6):905-8. doi: 10.1136/ard.2011.151563.

PMID:
21540200

Supplemental Content

Support Center